Joanie M Thelen1, Sharon G Lynch2, Amanda S Bruce1, Laura M Hancock3, Jared M Bruce4. 1. Department of Psychology, University of Missouri - Kansas City, Kansas City, MO, United States. 2. Landon Center on Aging, University of Kansas Medical Center, Kansas City, KS, United States. 3. Alpert Medical School of Brown University, Providence, RI, United States. 4. Department of Psychology, University of Missouri - Kansas City, Kansas City, MO, United States. Electronic address: brucejm@umkc.edu.
Abstract
OBJECTIVE: Patients with multiple sclerosis (MS) commonly use a variety of medications to slow disease progression, alleviate symptoms, and treat comorbid conditions. Polypharmacy has been linked to adverse outcomes in other patient groups, but has not been studied extensively in MS. We investigated the impact of polypharmacy on fatigue, objective neuropsychological performance, and subjective cognitive impairment in a sample of patients with MS. METHODS: MS patients (n=85) completed a medication inventory, self-report questionnaires, and a battery of neurocognitive tests. MS patients with polypharmacy were compared to MS patients without polypharmacy, using multivariate analysis of covariance (MANCOVA). RESULTS: After controlling for disease characteristics, MS patients with polypharmacy (n=28) exhibited prospective memory deficits and reported significantly more fatigue and subjective cognitive problems than MS patients without polypharmacy. CONCLUSION: Clinicians and patients should carefully weigh the costs and benefits of prescribing multiple medications, as these may contribute to iatrogenic fatigue and cognitive problems in MS. Moreover, researchers should account for polypharmacy when conducting studies examining fatigue and cognition in MS.
OBJECTIVE:Patients with multiple sclerosis (MS) commonly use a variety of medications to slow disease progression, alleviate symptoms, and treat comorbid conditions. Polypharmacy has been linked to adverse outcomes in other patient groups, but has not been studied extensively in MS. We investigated the impact of polypharmacy on fatigue, objective neuropsychological performance, and subjective cognitive impairment in a sample of patients with MS. METHODS: MS patients (n=85) completed a medication inventory, self-report questionnaires, and a battery of neurocognitive tests. MS patients with polypharmacy were compared to MS patients without polypharmacy, using multivariate analysis of covariance (MANCOVA). RESULTS: After controlling for disease characteristics, MS patients with polypharmacy (n=28) exhibited prospective memory deficits and reported significantly more fatigue and subjective cognitive problems than MS patients without polypharmacy. CONCLUSION: Clinicians and patients should carefully weigh the costs and benefits of prescribing multiple medications, as these may contribute to iatrogenic fatigue and cognitive problems in MS. Moreover, researchers should account for polypharmacy when conducting studies examining fatigue and cognition in MS.
Authors: Ashley K Miller; Michael R Basso; Philip J Candilis; Dennis R Combs; Steven Paul Woods Journal: J Clin Exp Neuropsychol Date: 2014-10-23 Impact factor: 2.475
Authors: Roger S McIntyre; Holly X Xiao; Kahlood Syeda; Maj Vinberg; Andre F Carvalho; Rodrigo B Mansur; Nadia Maruschak; Danielle S Cha Journal: CNS Drugs Date: 2015-07 Impact factor: 5.749
Authors: George A Jelinek; Tracey J Weiland; Emily J Hadgkiss; Claudia H Marck; Naresh Pereira; Dania M van der Meer Journal: Neurol Res Date: 2015-04-23 Impact factor: 2.448
Authors: Rosalind Kalb; Meghan Beier; Ralph Hb Benedict; Leigh Charvet; Kathleen Costello; Anthony Feinstein; Jeffrey Gingold; Yael Goverover; June Halper; Colleen Harris; Lori Kostich; Lauren Krupp; Ellen Lathi; Nicholas LaRocca; Ben Thrower; John DeLuca Journal: Mult Scler Date: 2018-10-10 Impact factor: 6.312